HIV/AIDS vaccine: Phase I started

GeoVax started a 1-year, double-blind, placebo-controlled, U.S. and Thai Phase I trial in 120 healthy volunteers. About 48 subjects in the Part A of the study will receive escalating doses whereas 72 ...